TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04394182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: 100/400 mg/12h; 7-10 days
Study: NCT01487785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225+gemcitabine
Description: Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
Study: NCT02605967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator choice of chemotherapy
Description: Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
Study: NCT03107299

Intervention type: OTHER
Group type: OTHER
Intervention: Communication methods to encourage adherence
Description: Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)

Intervention type: OTHER
Group type: OTHER
Intervention: Communication methods to encourage adherence
Description: Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)

Intervention type: OTHER
Group type: OTHER
Intervention: Communication methods to encourage adherence
Description: Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
Study: NCT02088411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wobenzym

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02145520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: use of placebo with standard therapy
Study: NCT04118426

Intervention type: RADIATION
Intervention: Cognitive testing
Description: Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI).

Intervention type: RADIATION
Intervention: Cognitive testing
Description: Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI).
Study: NCT02812537

Intervention type: OTHER
Intervention: patients with conduct disorders
Description: interview with a specialist
Study: NCT00804011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATC
Description: Automatic tube compensation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSV
Description: Pressure support ventilation
Study: NCT01355835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation (ACTIVA PC, Medtronic)
Description: High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
Study: NCT00631241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
Study: NCT04394182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg/12h
Study: NCT01355835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation (ACTIVA PC, Medtronic)
Description: High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
Study: NCT00631241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Lymphatic Mapping
Description: Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
Study: NCT00705965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information session
Description: One information session about living with heart disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual cardiological care
Description: Usual cardiological care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual cardiological care
Description: Usual cardiological care
Study: NCT03367351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Education
Description: Completion of a CGM specific web-based educational intervention that includes a series of online learning modules.
Study: NCT03569423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transepithelial photorefractive keratectomy
Description: ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial photorefractive keratectomy
Description: ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
Study: NCT01632215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentine
Description: Gabapentine 600 mg 01 dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill 01 dose
Study: NCT02918058

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MedSafer
Description: MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MedSafer
Description: MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MedSafer
Description: MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
Study: NCT03997253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and urine samples
Description: various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12 and intraoperative bile collection
Study: NCT04509154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal pain therapy
Description: For the elaboration of the contents of the multi-component treatment of the mobile device application (APP), a set of guidelines has been developed for the care of one's own health, based on scientific evidence and adapted to the language of citizens, applying participatory methodology (Loewenson et al. 2014) and consensus, both by professionals (physicians,, nurses, psychologists, pharmacists, social educators and health professionals), and expert patients, who guarantee their validity, allowing the analysis and selection of the interventions that respond to the health problem. This intervention consists in the implementation of a protocol of standard activities of the interactive psychosocial therapy type.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized treatment.
Description: Face-to-face health education sessions led by nurses and physicians, with the possibility to have access to a non-interactive website with pain management materials from a self-help approach.
Study: NCT03045536

Intervention type: DEVICE
Intervention: MML (Fa. ESKA/Orthodynamics)
Description: Classification of complications according to MSTS
Study: NCT03367351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Engagement in peer-led CGM specific discussion boards
Study: NCT03116776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Walnut Shell Glasses Moxibustion
Description: Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate eye drops
Description: One drop for each eye, four times per day for over 4 weeks.
Study: NCT02093728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
Study: NCT03367351

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care - serves as the control group for the treatment arm
Study: NCT04394182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg/24h, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Description: 4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: prophylactic doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: 250mg x 3 boluses
Study: NCT02093728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
Study: NCT01006486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation clinic
Description: Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard anticoagulation care
Description: Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
Study: NCT01482403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: total daily dose of 1000 mg or 1200 mg for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: total daily dose of 1000 mg or 1200 mg for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: total daily dose of 1000 mg or 1200 mg for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 microgram subcutaneous once a week for 24 weeks
Study: NCT04394182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 600mg single dose
Study: NCT01482403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 microgram subcutaneous once a week for 48 weeks
Study: NCT03156361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDV insulin lispro 100 UNIT/mL
Description: Hepatic Directed Vesicle (HDV) added to commercial insulin lispro

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro 100 Units/mL
Description: Sterile Water for Injection added to commercial insulin lispro
Study: NCT01482403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 microgram subcutaneous once a week for 48 weeks
Study: NCT04551144

Intervention type: DRUG
Intervention: testosterone cypionate
Description: intramuscular injection every 2 weeks. Dose will be titrated based on blood levels
Study: NCT01482403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: 800 mg three times a day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: 800 mg three times a day for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mericitabine
Description: 1000 mg twice daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mericitabine
Description: 1000 mg twice daily for 24 weeks
Study: NCT04551144

Intervention type: DRUG
Intervention: Estradiol Valerate
Description: intramuscular injection every week. Dose will be titrated based on blood levels
Study: NCT01482403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mericitabine placebo
Description: mericitabine placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: boceprevir placebo
Description: boceprevir placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: boceprevir
Description: 800 mg three times a day for 44 weeks
Study: NCT00892450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin and darifenacin
Description: Participants with overactive bladder will take each medication for 4 weeks.
Study: NCT02380157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaleorid, 750mg (trade name), Potassium chloride (active substance)
Description: 4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
Study: NCT02116218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vaccaria seed
Description: We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
Study: NCT02775201

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plantaris release under ultrasound guidance
Description: In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
Study: NCT04280328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciforadenant
Description: 100 mg orally twice daily for 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: 16 mg/kg administered intravenously as follows based on 28-day cycles:~* Cycles 1 - 2: Days 1, 8, 15, and 22~* Cycles 3 - 6: Days 1 and 15~* Cycles 7 - 24: Day 1
Study: NCT02775201

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plantaris excision surgically
Description: In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
Study: NCT02428985

Intervention type: DRUG
Intervention: Riociguat (ADEMPAS, BAY63-2521)
Description: The treatment of Riociguat should comply with the local product information
Study: NCT03739840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil in different dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil in different dosages.
Study: NCT02821598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Limb pattern with flexion - abduction - external rotation
Description: The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Limb pattern with flexion - adduction - external rotation with knee flexion
Description: The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Limb pattern with flexion - abduction - internal rotation with knee flexion
Description: The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifting to the right
Description: The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sit to Stand
Description: Subjects will be sitting on a chair without armrests with ankles positioned at approximately 10 degrees of dorsiflexion. Knees will be kept at approximately 100 degrees of flexion. During the task, the participant will be instructed to stand from the sitting position while keeping their arms crossed over the chest. The examiner will give the command ready - set - go. The task will be performed three times.
Study: NCT01827410

Intervention type: PROCEDURE
Intervention: Ventral hernia repair
Study: NCT01153854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril
Description: oral racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril
Description: oral racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo groups
Description: Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo groups
Description: Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days
Study: NCT05218564

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen Therapy
Description: During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compressed Medical Air
Description: During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
Study: NCT04857450

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Etomidate
Description: Received Etomidate 0.2 mg/kg IV over 30 seconds, followed by Etomidate 0.05 mg/kg IV and repeated when needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Received Ketamine 0.5 mg/kg IV over 30 seconds then Etomidate 0.1 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.